pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,837 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
    The newly approved over-the-counter CGM offers a new approach to tackling childhood obesity but also raises a host of questions.
    STAT · 19d ago↗ source
  • STAT+: Trump administration pursues more durable changes to science policy after setbacks in court
    The White House has proposed sweeping changes to the bedrock regulation undergirding all federal contracts, empowering the executive branch to direct research, terminate grants, and external scient…
    STAT · 19d ago↗ source
  • Vertex's Crinetics deal points to big ambitions for cystic fibrosis leader
    Vertex Pharmaceuticals' $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry. Long a biotech s…
← prev
page 19 of 74
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 20d ago
↗ source
  • Tampa General kicks off legal fight over Lilly's 340B restrictions
    Tampa General Hospital sued Eli Lilly for halting its 340B discounts, kicking off a broader fight over whether pharmaceutical companies can condition drug discounts on new claims data requirements.…
    Endpoints · 20d ago↗ source
  • Vera's IgAN approval kicks off competition with Otsuka
    Vera Therapeutics’ fusion protein atacicept got an accelerated approval on Tuesday for a chronic autoimmune disease that damages the kidneys. The drug will be marketed as Trutakna for immunoglobu…
    Endpoints · 20d ago↗ source
  • STAT+: FDA approves Vera Therapeutics kidney disease treatment
    The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
    STAT · 20d ago↗ source
  • Oberland pours up to $400M into MeiraGTx eye gene therapies
    <figure><div><img src="https://imgproxy.divecdn.com/nnTWCzHBd9_O2uNBVPF6xmxcO0M-nRFDpca5z-2Xchs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDMwNzQzODA0LmpwZ…
    BioPharma Dive · 20d ago↗ source
  • Kailera says obesity pill succeeds in late-stage trial in China
    <figure><div><img src="https://imgproxy.divecdn.com/sHvIDEWnHWODDKUtbWbg7nZxoWKQNqB4C54nc9z4iH4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc4ODI5MzYyLmpwZ…
    BioPharma Dive · 20d ago↗ source
  • STAT+: The crumbling employer-based health insurance system
    Today's D.C. Diagnosis newsletter covers maintaining diversity in drug trials and troubling trends in employer-based health insurance.
    STAT · 20d ago↗ source
  • Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
    Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…
    Endpoints · 20d ago↗ source
  • Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
    The GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety pro…
    Endpoints · 20d ago↗ source
  • STAT+: Compass says depression drug has long-lasting benefits
    Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
    STAT · 20d ago↗ source
  • STAT+: America’s employer health insurance is decaying
    STAT's Bob Herman examines the under-the-radar crisis brewing in employer-based health insurance.
    STAT · 20d ago↗ source
  • Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half
    Biopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $1…
    Endpoints · 20d ago↗ source
  • MeiraGTx strikes royalty deal; Fore's 2023 Series D continues
    Plus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...
    Endpoints · 20d ago↗ source
  • STAT+: ‘Secret shopper’ study probes GLP-1 telehealth sites
    In this edition of STAT Health Tech: A 'secret shopper' study of telehealth sites prescribing GLP-1s, news about Epic, Anthropic, and brain implants.
    STAT · 20d ago↗ source
  • Conquering Medicare's ACCESS program
    There was so much excitement when CMS announced the ACCESS program. Finally, a way for digital health companies to make their mark on Medicare! A program that pays only if patients get better! Bu…
    Endpoints · 20d ago↗ source
  • Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
    <p>Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.</p>
    BioPharma Dive · 20d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
    Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
    STAT · 20d ago↗ source
  • How digital health companies are planning to conquer CMS ACCESS
    A new Medicare experiment to manage seniors’ chronic diseases will pay some digital health companies only about as much in a year as they might earn for a couple of patient visits from commercial i…
    Endpoints · 20d ago↗ source
  • Ebola outbreak exposes a fractured outbreak response system
    The costly threat to employer-based health care, Gen Z doctors, and more health news
    STAT · 20d ago↗ source
  • Vera Therapeutics wins FDA nod for closely watched kidney disease drug
    <figure><div><img src="https://imgproxy.divecdn.com/f5a4VRDXQg-SwH2yBDKHbtLeyVHpX8cemnSbe-t-6xU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNDk4X0F5Q…
    BioPharma Dive · 20d ago↗ source
  • STAT+: For a Georgia entrepreneur, health coverage has never been affordable
    Amy Bielawski is one of the 30 million people who run their own businesses. She's gone most of her life without health insurance.
    STAT · 20d ago↗ source
  • STAT+: America’s small businesses are giving up on health insurance
    America's employer-based health insurance system is crumbling. STAT investigates why, in our new series, “Out of Pocket, Out of Reach.”
    STAT · 20d ago↗ source
  • STAT+: This whistleblower took on a health insurance giant and a political machine. She’s not stopping there
    America’s employers must stop acting helpless in the face of health care industry profiteering, Chris Deacon says.
    STAT · 20d ago↗ source